Canaccord Genuity

Product is designed to treat life-threatening conditions triggered when the body’s immune system “goes rogue” in response to infections such as COVID-19.
Canaccord Genuity's third-quarter earnings got a major lift from a flurry of deals in the Canadian cannabis sector, which helped the investment bank see its net income rise more than 500 per cent y
Nothing was going to rain on Kinaxis’ parade after the Ottawa-based tech firm closed a successful initial public offering on the Toronto Stock Exchange this week.